Diabetes Care, Vol 18, Issue 12 1557-1565, Copyright © 1995 by American Diabetes Association

ARTICLES

GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis

LK Niskanen, T Tuomi, J Karjalainen, LC Groop and MI Uusitupa
Department of Clinical Nutrition, University of Kuopio, Finland. lniskane@messi.uku.fi

OBJECTIVE: To study the frequency of antibodies to glutamic acid decarboxylase (GAD) and islet cell antibodies (ICAs) and their predictive value with respect to the development of insulin deficiency in 133 newly diagnosed middle-aged patients with non-insulin-dependent diabetes mellitus (NIDDM) and in 126 control subjects and to study the persistence of GAD antibodies in diabetic patients during the follow-up. RESEARCH DESIGN AND METHODS: The study participants consisted of a well-characterized group of 133 middle-aged newly diagnosed patients with NIDDM and 126 control subjects. The follow-up examinations were performed 5 and 10 years after the baseline. The development of absolute and relative insulin deficiency was based on a stimulated C-peptide level that was undetectable or < 0.70 nmol/l, respectively. GAD antibodies were measured retrospectively from stored samples. RESULTS: The overall prevalence of GAD antibody and ICA positivity at the time of diagnosis was 9.0 and 3.8% in diabetic patients and 1.6 and 0% in the control population, respectively. During the 10-year follow-up, 3 (2.3%) and 10 (7.5%) of the diabetic patients developed absolute and relative insulin deficiency, respectively. Of these, two (67%) and six (60%) had been GAD antibody-positive at the time of diagnosis. The sensitivity and specificity of the GAD antibody to predict absolute or relative insulin deficiency were 67 vs. 94% and 60 vs. 95%, while corresponding figures for ICA were 33 vs. 97% and 20 vs. 98%, respectively. The negative predictive value of GAD antibody testing was higher than positive predictive value (97 vs. 50%). During the follow-up, low-grade GAD antibody positivity showed an evanescent nature, whereas the high levels were quite persistent. CONCLUSIONS: In an unselected population of newly diagnosed NIDDM patients, the prevalence of latent autoimmune diabetes in adults was < 10%. While GAD antibody and ICA measured at the time of diagnosis of NIDDM are equally specific predictors of subsequent insulin dependency, the GAD antibody may have a higher sensitivity. Therefore, measurements of GAD antibody may aid the clinician in the choice of treatment of these patients.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A W van Deutekom, M T Nurmohamed, M J L Peters, I C van Eijk, B A C Dijkmans, D Hamann, R J Heine, and S Simsek Methotrexate and its effect on the anti-GAD titre in two patients with rheumatoid arthritis and diabetes mellitus Ann Rheum Dis, July 1, 2008; 67(7): 1051 - 1052. [Full Text] [PDF]

				K. K. Babington and D. E. DeWitt The Meaning of Autoantibody Titers, Exercise, and Alcohol in a Thin 65-Year-Old Man Hospitalized for Cholangitis and Coincidental New Diabetes Clin. Diabetes, October 1, 2006; 24(4): 185 - 186. [Full Text] [PDF]

				E. Barinas-Mitchell, L. H. Kuller, S. Pietropaolo, Y.-J. Zhang, T. Henderson, and M. Pietropaolo The Prevalence of the 65-Kilodalton Isoform of Glutamic Acid Decarboxylase Autoantibodies by Glucose Tolerance Status in Elderly Patients from the Cardiovascular Health Study J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2871 - 2877. [Abstract] [Full Text] [PDF]

				T Reinehr, E Schober, S Wiegand, A Thon, R Holl, and on behalf of the DPV-Wiss Study Group {beta}-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch. Dis. Child., June 1, 2006; 91(6): 473 - 477. [Abstract] [Full Text] [PDF]

				S. Fourlanos, C. Perry, M. S. Stein, J. Stankovich, L. C. Harrison, and P. G. Colman A Clinical Screening Tool Identifies Autoimmune Diabetes in Adults Diabetes Care, May 1, 2006; 29(5): 970 - 975. [Abstract] [Full Text] [PDF]

				S Genovese, E Bazzigaluppi, D Goncalves, A Ciucci, M G Cavallo, F Purrello, M Anello, C M Rotella, G Bardini, O Vaccaro, et al. Clinical phenotype and {beta}-cell autoimmunity in Italian patients with adult-onset diabetes. Eur. J. Endocrinol., March 1, 2006; 154(3): 441 - 447. [Abstract] [Full Text] [PDF]

				T. Tuomi Type 1 and Type 2 Diabetes: What Do They Have in Common? Diabetes, December 1, 2005; 54(suppl_2): S40 - S45. [Abstract] [Full Text] [PDF]

				I. Vauhkonen, L. Niskanen, M. Knip, L. M. Mykkanen, S. Haffner, M. Uusitupa, and M. Laakso Subtle hyperproinsulinaemia characterises the defective insulin secretory capacity in offspring of glutamic acid decarboxylase antibody-positive patients with latent autoimmune diabetes mellitus in adults Eur. J. Endocrinol., August 1, 2005; 153(2): 265 - 273. [Abstract] [Full Text] [PDF]

				M. Maioli, E. Alejandro, G. Tonolo, L. K. Gilliam, L. Bekris, C. S. Hampe, D. A. Obinu, A. Manconi, L. Puddu, K. Lynch, et al. Epitope-Restricted 65-Kilodalton Glutamic Acid Decarboxylase Autoantibodies among New-Onset Sardinian Type 2 Diabetes Patients Define Phenotypes of Autoimmune Diabetes J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5675 - 5682. [Abstract] [Full Text] [PDF]

				E. Barinas-Mitchell, S. Pietropaolo, Y.-J. Zhang, T. Henderson, M. Trucco, L. H. Kuller, and M. Pietropaolo Islet Cell Autoimmunity in a Triethnic Adult Population of the Third National Health and Nutrition Examination Survey Diabetes, May 1, 2004; 53(5): 1293 - 1302. [Abstract] [Full Text] [PDF]

				J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001 Diabetes, January 1, 2004; 53(1): 250 - 264. [Abstract] [Full Text] [PDF]

				D. E. Laaksonen, H.-M. Lakka, L. K. Niskanen, G. A. Kaplan, J. T. Salonen, and T. A. Lakka Metabolic Syndrome and Development of Diabetes Mellitus: Application and Validation of Recently Suggested Definitions of the Metabolic Syndrome in a Prospective Cohort Study Am. J. Epidemiol., December 1, 2002; 156(11): 1070 - 1077. [Abstract] [Full Text] [PDF]

				P. Vague and L. Nguyen Rationale and Methods for the Estimation of Insulin Secretion in a Given Patient: From Research to Clinical Practice Diabetes, February 1, 2002; 51(90001): S240 - 244. [Abstract] [Full Text] [PDF]

				P. Pozzilli and U. Di Mario Autoimmune Diabetes Not Requiring Insulin at Diagnosis (Latent Autoimmune Diabetes of the Adult): Definition, characterization, and potential prevention Diabetes Care, August 1, 2001; 24(8): 1460 - 1467. [Abstract] [Full Text] [PDF]

				H. Borg, A. Gottsater, M. Landin-Olsson, P. Fernlund, and G. Sundkvist High Levels of Antigen-Specific Islet Antibodies Predict Future {beta}-Cell Failure in Patients with Onset of Diabetes in Adult Age J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3032 - 3038. [Abstract] [Full Text] [PDF]

				E. H. Hathout, W. Thomas, M. El-Shahawy, F. Nahab, and J. W. Mace Diabetic Autoimmune Markers in Children and Adolescents With Type 2 Diabetes Pediatrics, June 1, 2001; 107(6): e102 - 102. [Abstract] [Full Text] [PDF]

				M. Fukui, Y. Kitagawa, N. Nakamura, and T. Yoshikawa Adult-Onset Type 1 Diabetes With DIDMOAD Syndrome-like Manifestations Arch Intern Med, March 12, 2001; 161(5): 767 - 768. [Full Text] [PDF]

				B Wesche, E Jaeckel, C Trautwein, H Wedemeyer, A Falorni, H Frank, A von zur Muhlen, M-P Manns, and G Brabant Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C Gut, March 1, 2001; 48(3): 378 - 383. [Abstract] [Full Text] [PDF]

				H. Li, E. Lindholm, P. Almgren, A. Gustafsson, C. Forsblom, L. Groop, and T. Tuomi Possible Human Leukocyte Antigen-Mediated Genetic Interaction between Type 1 and Type 2 Diabetes J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 574 - 582. [Abstract] [Full Text]

				I. Saito, A. R. Folsom, F. L. Brancati, B. B. Duncan, L. E. Chambless, and P. G. McGovern Nontraditional Risk Factors for Coronary Heart Disease Incidence among Persons with Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study Ann Intern Med, July 18, 2000; 133(2): 81 - 91. [Abstract] [Full Text] [PDF]

				A. Carlsson, G. Sundkvist, L. Groop, and T. Tuomi Insulin and Glucagon Secretion in Patients with Slowly Progressing Autoimmune Diabetes (LADA) J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 76 - 80. [Abstract] [Full Text]

				A. Falorni, G. Gambelunghe, F. Forini, G. Kassi, A. Cosentino, P. Candeloro, G. B. Bolli, P. Brunetti, and F. Calcinaro Autoantibody Recognition of COOH-Terminal Epitopes of GAD65 Marks the Risk for Insulin Requirement in Adult-Onset Diabetes Mellitus J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 309 - 316. [Abstract] [Full Text]

				M. R. Batstra, A. van Driel, J. S. Petersen, C. A. van Donselaar, M. J. van Tol, G. J. Bruining, D. E. Grobbee, T. Dyrberg, and H.-J. Aanstoot Glutamic Acid Decarboxylase Antibodies in Screening for Autoimmune Diabetes: Influence of Comorbidity, Age, and Sex on Specificity and Threshold Values Clin. Chem., December 1, 1999; 45(12): 2269 - 2272. [Full Text] [PDF]

				J. E. Gerich The Genetic Basis of Type 2 Diabetes Mellitus: Impaired Insulin Secretion versus Impaired Insulin Sensitivity Endocr. Rev., August 1, 1998; 19(4): 491 - 503. [Abstract] [Full Text] [PDF]

				H. Borg, P. Fernlund, and G. Sundkvist Measurement of antibodies against glutamic acid decarboxylase 65 (GADA): two new 125I assays compared with [35S]GAD 65-ligand binding assay Clin. Chem., May 1, 1997; 43(5): 779 - 785. [Abstract] [Full Text] [PDF]